Abstract: Provided are pharmacological methods of inducing through a unified set of molecular mechanisms the maturation of stem cells, methods of promoting mitochondrial biogenesis in a cell and tissue, methods of reducing pluripotency in a stem cell, and methods of promoting differentiation of a stem cell. In particular, the invention relates to methods for promoting tissue growth and/or tissue repair and/or improving tissue survival, preventing and treating fibrotic lesions and disorders.

Abstract: The present disclosure provides, in part, a self-contained, point-of-care device for the early detection of infection, or other pathologic conditions that can lead to system inflammation, by the detection of the endogenous gaseous mediator nitric oxide (NO.) and methods of use.

Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.

Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.

Abstract: The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.

Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.

Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event of on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.

Abstract: Patients with pathologic conditions involving constriction or proliferation of smooth muscle or disease associated with cysteine containing proteins, or who are at risk for such, are administered a therapeutically effective amount of a nitric oxide (NO) donor which is insufficient to acutely lower mean arterial blood pressure or pulmonary artery pressure by more than 10%. In one subgenus, NO donor is administered to modify red blood cell membrane receptors to prevent red blood cells from causing vasoconstriction. A related method which allows increased dosage of NO donor without acutely lowering mean arterial blood pressure comprises administering the NO donor into an artery of the patient. In another method, patients having a cardiovascular syndrome, or who are at risk for such, are administered a therapeutically effective amount of thiol which does not acutely affect blood pressure to a significant degree.

Abstract: Nitric oxide-specific electrodes are useful for in situ detection of nitric oxide in biomedical applications and have at least a surface region thereof which is capable of forming complexes with nitric oxide, for example, nitrosyl complexes. The nitric oxide complexes formed at the surface of the electrodes apparently increase the concentration of nitric oxide available for detection, thereby leading to significantly improved relative responses as compared to other known nitric oxide electrode materials. Most preferably, the electrode has at least an exterior surface region which contains ruthenium and/or at least one oxide of ruthenium. The electrodes are advantageously conditioned in saline solution at +675 mV for about two hours.

Abstract: Nitric oxide-specific electrodes are useful for in situ detection of nitric oxide in biomedical applications and have at least a surface region capable of forming complexes with nitric oxide. The nitric oxide complexes formed at the surface of the electrodes apparently increase the concentration of nitric oxide available for detection, leading to significantly improved relative responses as compared to other known nitric oxide electrode materials. The electrode has at least an exterior surface region which contains ruthenium and/or at least one oxide of ruthenium. The electrodes are pre-conditioned at a potential, or potentials, different than the working potential of the electrode, followed by further conditioning at the working potential. Direct response to nitric oxide has been observed for ruthenium electrodes at or below potentials about +675 mV vs. Ag/AgCl, while ruthenium electrodes paradoxical response to nitric oxide has been observed at potentials above +675 mV vs. Ag/Cl.

Abstract: Nitric oxide-specific electrodes are useful for in situ detection of nitric oxide in biomedical applications and have at least a surface region thereof which is capable of forming complexes with nitric oxide, for example, nitrosyl complexes. The nitric oxide complexes formed at the surface of the electrodes apparently increase the concentration of nitric oxide available for detection, thereby leading to significantly improved relative responses as compared to other known nitric oxide electrode materials. Most preferably, the electrode has at least an exterior surface region which contains ruthenium and/or at least one oxide of ruthenium. The electrodes are advantageously conditioned in saline solution at +675 mV for about two hours.

Abstract: Quaternary amine-containing ether lipid analogs of the formulaR.sub.1 --X--R.sub.2 --N.sup.+ (R.sub.3) (R.sub.4) (R.sub.5) Z.sup.-are disclosed. R.sub.1 represents a hydrophobic group and R.sub.2 represents the backbone of the molecule, with the quaternary amine being linked directly to the backbone. Pharmaceutical compositions including these compounds and methods of combating tumors with these compounds are disclosed. Also disclosed is a method of combating viral infections with both these compounds and ET-18-OMe and its analogs.

Abstract: Ether lipid nucleoli covalent conjugates and derivatives thereof are disclosed, along with pharmaceutical compositions containing the same and methods of using the same to combat HIV-1 infections. Illustrative are 3'-Azido-3'-deoxythmidine-5'-monophosphate-D,L-3-octadecanamido-2-ethoxypr opane and 3'-Azido-3'-deoxythymidine-5'-butyrate-.gamma.-N,N,N-trimethyl -ammonium-.beta.-(1-phospho-2-ethoxy-3-hexadecyloxypropane).

Abstract: The present invention relates to use of alkylaryl polyether alcohol polymers as antioxidants to suppress certain oxidant chemical reactions that cause tissue injury and disease in mammals. Disclosed is a method of inhibiting oxidants using alkylaryl polyether alcohol polymers. More particularly, disclosed is a method for the treatment of mammalian disease entities related to overproduction of partially reduced oxygen species comprising administering to a mammal a treatment effective amount of an alkylaryl polyether alcohol polymer. The mammalian disease entities include, but are not limited to, myocardial infarction, stroke, adult respiratory distress syndrome, oxygen toxicity of the lung, lung injury from asbestos, Parkinson's disease, thermal and solar burns of the skin, and injury to the gastrointestinal tract from nonsteroidal anti-inflammatory agents.

Abstract: A method and medicament for the inhibition of oxidants comprising administering a treatment effective amount of alkylaryl polyether alcohol polymers to a chemical or biologic system in need thereof. The medicament is preferably administered by aerosolization into the mammalian respiratory system. The medicament may also be applied to the mammalian skin. Preferably, the medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, isotonic saline, normal saline, petrolatum based ointments and U.S.P. cold cream.

Abstract: A non-invasive method for detecting deep venous thrombosis in a human body wherein changes are effected in the amount of deoxyhemoglobin in the body limb by trapping blood in the venous system for a determinate time period and then releasing the trapped blood in the venous system. During the period that the changes in the amount of deoxyhemoglobin are effected, first and second light sources emit light of two selected wavelengths which penetrate into the deep venous system of the body limb so that the reflectance contributions can be used to measure changes in the flow and amount of deoxyhemoglobin and to thereby detect the presence or absence of deep venous thrombosis.

Abstract: A method and apparatus for measuring oxidative metabolism in an internal organ or tissue of interest wherein a percutaneous intravascular approach is utilized to bring a light-transmitting and receiving scope into contact with the site to be assessed. The tip of the scope is adapted so that the light-transmitting optical fiber(s) and light-receiving optical fiber(s) are in divergent relationship so as to increase the photon pathlength through the tissue of interest to provide optical information from a substantial volume of tissue relative thereto.

Abstract: A method and apparatus for measuring oxidative metabolism in an internal organ or tissue of interest wherein a percutaneous intravascular approach is utilized to bring a light-transmitting and receiving scope into contact with the site to be assessed. The tip of the scope is adapted so that the light-transmitting optical fiber(s) and light-receiving optical fiber(s) are in divergent relationship so as to increase the photon pathlength through the tissue of interest to provide optical information from a substantial volume of tissue relative thereto.